Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants

被引:3
作者
Principi, Nicola [1 ]
Autore, Giovanni [2 ]
Perrone, Serafina [3 ]
Esposito, Susanna [2 ,4 ]
机构
[1] Univ Milan, Milan, Italy
[2] Univ Parma, Pietro Barilla Childrens Hosp, Dept Med & Surg, Pediat Clin, Parma, Italy
[3] Univ Parma, Pietro Barilla Childrens Hosp, Dept Med & Surg, Neonatol Unit, Parma, Italy
[4] Univ Parma, Pietro Barilla Childrens Hosp, Dept Med & Surg, Via Gramsci 14, I-43126 Parma, Italy
关键词
RSV; antiviral; monoclonal antibodies; nirsevimab; respiratory tract infection; vaccines; HUMANIZED MONOCLONAL-ANTIBODY; FUSION INHIBITOR; F-PROTEIN; REDUCES HOSPITALIZATION; PALIVIZUMAB PROPHYLAXIS; NEUTRALIZING EPITOPES; CONTROLLED-TRIAL; IMMUNE GLOBULIN; YOUNG-CHILDREN; HEALTHY WOMEN;
D O I
10.1080/14656566.2023.2197590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionRespiratory syncytial virus (RSV) is a common respiratory virus with a huge impact on patients, the healthcare system, and society worldwide. Very few effective chances of prevention and treatment of RSV infection are available.Areas coveredIn this paper, knowledge on RSV characteristics and current stage of development of new pharmacological measures against this virus are discussed.Expert opinionIn recent years, the structure of RSV was explored in depth and several pharmacologic measures potentially effective for prevention and treatment of RSV infection and disease were identified. These new measures have the aim to overcome the limitations of palivizumab and ribavirin. Strategies to protect infants through immunization of pregnant women and/or the use of more effective monoclonal antibodies were developed. At the same time, it was defined which vaccines could be administered to unprimed infants to avoid the risk of enhanced respiratory disease and which vaccines could be effective in older patients and in subjects with reduced immune system efficiency. Finally, a great number of new antiviral drugs targeting the RSV proteins that allow RSV entering host cells or regulate virus replication were produced. Although further studies are needed, some preparations seem effective and safe, making the future of RSV infection prevention and treatment less gloomy.
引用
收藏
页码:747 / 762
页数:16
相关论文
共 162 条
[1]   RSV Vaccines, Finally Within Reach, Could Prevent Tens of Thousands of Yearly Deaths [J].
Abbasi, Jennifer .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (03) :204-206
[2]   Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease [J].
Acosta, Patricio L. ;
Caballero, Mauricio T. ;
Polack, Fernando P. .
CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (03) :189-195
[3]  
Adis insight, PAL BIOS MABXIENCE
[4]   EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge [J].
Ahmad, Alaa ;
Eze, Kingsley ;
Noulin, Nicolas ;
Horvathova, Veronika ;
Murray, Bryan ;
Baillet, Mark ;
Grey, Laura ;
Mori, Julie ;
Adda, Nathalie .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) :655-666
[5]   A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults [J].
Aliprantis, Antonios O. ;
Wolford, Dennis ;
Caro, Luzelena ;
Maas, Brian M. ;
Ma, Hua ;
Montgomery, Diana L. ;
Sterling, Laura M. ;
Hunt, Allen ;
Cox, Kara S. ;
Vora, Kalpit A. ;
Roadcap, Brad A. ;
Railkar, Radha A. ;
Lee, Andrew W. ;
Stoch, S. Aubrey ;
Lai, Eseng .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (05) :556-566
[6]   A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults [J].
Aliprantis, Antonios O. ;
Shaw, Christine A. ;
Griffin, Paul ;
Farinola, Nicholas ;
Railkar, Radha A. ;
Cao, Xin ;
Liu, Wen ;
Sachs, Jeffrey R. ;
Swenson, Christine J. ;
Lee, Heather ;
Cox, Kara S. ;
Spellman, Daniel S. ;
Winstead, Colleen J. ;
Smolenov, Igor ;
Lai, Eseng ;
Zaks, Tal ;
Espeseth, Amy S. ;
Panther, Lori .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (05) :1248-1261
[7]   RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy [J].
Alvarez, Rene ;
Elbashir, Sayda ;
Borland, Todd ;
Toudjarska, Ivanka ;
Hadwiger, Philipp ;
John, Mathias ;
Roehl, Ingo ;
Morskaya, Svetlana Shulga ;
Martinello, Rick ;
Kahn, Jeffrey ;
Van Ranst, Mark ;
Tripp, Ralph A. ;
DeVincenzo, John P. ;
Pandey, Rajendra ;
Maier, Martin ;
Nechev, Lubomir ;
Manoharan, Muthiah ;
Kotelianski, Victor ;
Meyers, Rachel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3952-3962
[8]   Functional Features of the Respiratory Syncytial Virus G Protein [J].
Anderson, Larry J. ;
Jadhao, Samadhan J. ;
Paden, Clinton R. ;
Tong, Suxiang .
VIRUSES-BASEL, 2021, 13 (07)
[9]   NEUTRALIZATION OF RESPIRATORY SYNCYTIAL VIRUS BY INDIVIDUAL AND MIXTURES OF F-PROTEIN AND G-PROTEIN MONOCLONAL-ANTIBODIES [J].
ANDERSON, LJ ;
BINGHAM, P ;
HIERHOLZER, JC .
JOURNAL OF VIROLOGY, 1988, 62 (11) :4232-4238
[10]  
[Anonymous], 1986, FDA Drug Bull, V16, P7